MDT

88.48

+1.88%↑

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

MDT

88.48

+1.88%↑

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

MDT

88.48

+1.88%↑

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

MDT

88.48

+1.88%↑

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

MDT

88.48

+1.88%↑

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

3.28 6.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.06

Максимум

3.29

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+543.09% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-114M 274M
Предишно отваряне	-3.56
Предишно затваряне	3.28

Настроения в новините

By Acuity

20%

80%

38 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.04.2026 г., 23:25 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13.04.2026 г., 22:45 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13.04.2026 г., 18:03 ч. UTC

Печалби

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13.04.2026 г., 23:58 ч. UTC

Печалби

Review & Preview: Earnings Time -- Barrons.com

13.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13.04.2026 г., 23:20 ч. UTC

Пазарно говорене

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13.04.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13.04.2026 г., 21:26 ч. UTC

Значими събития в новините

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13.04.2026 г., 21:23 ч. UTC

Печалби

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13.04.2026 г., 21:16 ч. UTC

Печалби

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13.04.2026 г., 19:59 ч. UTC

Пазарно говорене

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13.04.2026 г., 19:50 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13.04.2026 г., 19:27 ч. UTC

Пазарно говорене

Значими събития в новините

Correction to Precious Metals Market Talk on April 9

13.04.2026 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13.04.2026 г., 18:43 ч. UTC

Пазарно говорене

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

543.09% нагоре

12-месечна прогноза

Среден 20 USD 543.09%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

38 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.